drug
omalizumab
Marketedupdated 6mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6all catalysts(0)
nothing on the calendar yet
Trials studying omalizumab
- phase3To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
- phase3Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
- phase2Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- phase3Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
- —Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
- —ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
- phase1A Study to Find a Suitable Dose of Exl-111 for Further Research
- —A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China
News(10)
- Protein degrader specialist Lycia prices $318M IPOFunds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.biopharma_dive · 26d ago
- Roche affirms sales outlook amid doubts about its futureLower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.biopharma_dive · 26d ago
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetAside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.biospace · 26d ago
- Lycia aims for $228M IPO to generate data on food allergy rival to XolairLycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for autoimmune, inflammatory and allergic diseases.fiercebiotech · 29d ago
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideAlkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.biopharma_dive · 1mo ago
- Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin conditionCelldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.fiercebiotech · 1mo ago
- Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trialCue Biopharma said Sunday its chronic hives candidate cleared a mid-stage trial, marking its first clinical data since its strategic pivot from cancer to immunology. In a Phase 2 China study in chr…endpoints · 1mo ago
- Cue chalks up phase 2 hives win for Xolair challengerA midstage study of Cue Biopharma’s hives drug candidate has hit its primary endpoint, emboldening the biotech to move the would-be challenger to Xolair into a phase 2b/3 trial.fiercebiotech · 1mo ago
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 3mo ago
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that